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Parkinson’s disease (PD) is an idiopathic, chronic neurodegener-
ative disorder characterized by degeneration of the dopaminergic
neurons of the substantia nigra pars compacta. Although the etiology
of this disease is still unknown, it has been associated with mitochon-
drial respiratory chain dysfunction, particularly with complex I defi-
ciency [1]. The first clue indicating an involvement of the mitochon-
drial respiratory chain in the etiology of PD came from the observa-
tion that contamination of a recreational drug by 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine caused irreversible PD symptoms in hu-
mans and nonhuman primates [2]. Additionally, Kosel et al. [3]
found, in the substantia nigra of neuropathologically confirmed idio-
pathic PD patients, a known missense mutation at nucleotide 3338
of the NADH dehydrogenase subunit 1 (ND1) mitochondrial DNA
(mtDNA) gene that changes the amino acid valine to alanine,
described previously by Chalmers et al. [4] in a control subject blood
DNA. In order to determine if the mtDNA ND1 is related with PD
and to find a peripheral tissue genetic risk factor of the disease, we
performed a polymerase chain reaction (PCR)-restriction fragment
length polymorphism analysis specific to mtDNA ND1 nucleotides
3337–3340 in 53 PD patients and 61 healthy age-matched controls.
Fifty-three patients, 29 female and 24 male (age range 37–81
years; mean 63.81 B 11.04 years), were followed in the Movement
Disorders Consultation at the Neurological Unit of the University
Hospital of Coimbra with the diagnosis of PD, as defined by the cri-
teria of the United Kingdom Parkinson’s Disease Society Brain
Bank. Sixty-one healthy age-matched control subjects free of progres-
sive neurological disorders, 32 female and 29 male (age range 37–84
years; mean 61.23 B 11.90 years), were recruited at the Neurological
Unit of the University Hospital of Coimbra, sharing a similar socio-
economic status as the parkinsonian patients. Total cellular DNA
was isolated from peripheral leukocytes of the subjects by standard
procedures, and then a fragment with 289 base pairs (bp) was ampli-
fied by using a T Gradient thermocycler (Biometra), for 30 cycles at
95°C for 30 s, 57°C for 30 s and 72°C for 30 s. The mastermix
included 0.25–0.5 Ìg of total cellular DNA, 200 ÌM dNTP (Amers-
ham Biosciences), 1 unit of Taq polymerase (Amersham Bio-
sciences), 1! Taq polymerase buffer (Amersham Biosciences) and
1 ÌM each of the primers 3397-5) (5)-AAAGGACAAGAGAAATA-
AGGCC-3)) and 3397-SEL (5)-GGGCCTTTGCGTAGTTGTCT-3),
specially designed with 1 mismatch for allele-specific PCR for detec-
tion of the wild-type allele at mtDNA ND1 nucleotide 3397) for a
reaction volume of 25 Ìl. The fragment obtained was digested with
the restriction endonuclease Csp6I (MBI-Fermentas) producing, if
no mutation was present, 2 fragments with 210 and 79 bp and
remaining uncut if a mutation was present. In order to verify if the
PCR product was an amplification of mtDNA genes or nuclear pseu-
dogenes, we performed the PCR reaction using 250 ng of total cellu-
lar DNA isolated from Ú0 cells, since these cells are devoid of mtDNA
[5].
The main finding of the present study was that all the PCR prod-
ucts of the 53 parkinsonian patients and the 61 healthy age-matched
controls were completely cut by the restriction endonuclease Csp6I,
meaning that we have not found any mutant in the 2 groups at the
mtDNA ND1 nucleotides 3337–3340. Another important fact is that
there was no amplification of the total cellular DNA isolated from Ú0
cells, confirming that we had amplified mtDNA genes and not
nuclear pseudogenes from parkinsonian patients and controls.
In conclusion, the mtDNA ND1 nucleotides 3337–3340 seem
unlikely to contribute to susceptibility to PD in the population under
study (central region of Portugal), and our results seem to rule out
that mutations in this sequence are a primary cause of sporadic PD.
However, this finding does not exclude involvement of the ND1 or
any other mtDNA complex I gene in the pathogenesis of PD. In fact,
somatic brain mitochondrial mutations may occur in subjects with-
out mutations in blood and our results relate to peripheral blood,
whereas Kosel et al. [3] report on brain tissue. Additionally, caution
is necessary when working with mtDNA because it has a high muta-
tion rate due to lack of a histone coat and an inadequate repair sys-
tem [6]. Given this vulnerability, free radical mtDNA damage may
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occur, particularly in aging and neurodegenerative disorders, causing
additional mtDNA injury, possibly initiating a vicious circle. We
believe that the study of peripheral tissues may be a step forward in
identifying possible genetic risk factors in earlier stages of the disease,
allowing earlier therapeutic approaches.
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